Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas

Pajtler, Kristian W.; Wen, Ji; Sill, Martin; Lin, Tong; Orisme, Wilda; Tang, Bo; H�bner, Jens-Martin; Ramaswamy, Vijay; Jia, Sujuan; Dalton, James D.; Haupfear, Kelly; Rogers, Hazel A.; Punchihewa, Chandanamali; Lee, Ryan; Easton, John; Wu, Gang; Ritzmann, Timothy A.; Chapman, Rebecca; Chavez, Lukas; Boop, Fredrick A.; Klimo, Paul; Sabin, Noah D.; Ogg, Robert; Mack, Stephen C.; Freibaum, Brian D.; Kim, Hong Joo; Witt, Hendrik; Jones, David T. W.; Vo, Baohan; Gajjar, Amar; Pounds, Stan; Onar-Thomas, Arzu; Roussel, Martine F.; Zhang, Jinghui; Taylor, J. Paul; Merchant, Thomas E.; Grundy, Richard; Tatevossian, Ruth G.; Taylor, Michael D.; Pfister, Stefan M.; Korshunov, Andrey; Kool, Marcel; Ellison, David W.

doi:10.1007/s00401-018-1877-0

All Outputs (5)

SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study (2022)
Journal Article
Ritzmann, T. A., Chapman, R. J., Kilday, J., Thorp, N., Modena, P., Dineen, R. A., …Grundy, R. G. (2022). SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study. Neuro-Oncology, 24(6), 936–948. https://doi.org/10.1093/neuonc/noac012

Background SIOP Ependymoma I was a non-randomised trial assessing event free and overall survival (EFS/OS) of non-metastatic intracranial ependymoma in children aged 3 to 21 years treated with a staged management strategy. A further aim was to asses... Read More about SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study.

EPEN-04. SIOP EPENDYMOMA I: FINAL RESULTS, LONG TERM FOLLOW-UP AND MOLECULAR ANALYSIS OF THE TRIAL COHORT: A BIOMECA CONSORTIUM STUDY (2021)
Journal Article
Ritzmann, T. A., Chapman, R. J., Macarthur, D., Mallucci, C., Kilday, J., Thorp, N., …Grundy, R. G. (2021). EPEN-04. SIOP EPENDYMOMA I: FINAL RESULTS, LONG TERM FOLLOW-UP AND MOLECULAR ANALYSIS OF THE TRIAL COHORT: A BIOMECA CONSORTIUM STUDY. Neuro-Oncology, 23(Supplement 1), i14. https://doi.org/10.1093/neuonc/noab090.054

Introduction Surgery and radiotherapy are established childhood ependymoma treatments. The efficacy of chemotherapy has been debated. We report final results of the SIOP Ependymoma I trial, with 12-year follow-up, in the context of a post-hoc analys... Read More about EPEN-04. SIOP EPENDYMOMA I: FINAL RESULTS, LONG TERM FOLLOW-UP AND MOLECULAR ANALYSIS OF THE TRIAL COHORT: A BIOMECA CONSORTIUM STUDY.

Integrative molecular characterization of pediatric spinal ependymoma: the UK Children’s Cancer and Leukaemia Group study (2021)
Journal Article
Ahmad, O., Chapman, R., Storer, L. C., Luo, L., Heath, P. R., Resar, L., …Lourdusamy, A. (2021). Integrative molecular characterization of pediatric spinal ependymoma: the UK Children’s Cancer and Leukaemia Group study. Neuro-Oncology Advances, 3(1), 1-13. https://doi.org/10.1093/noajnl/vdab043

Background Pediatric spinal ependymomas (SP-EPNs) are rare primary central nervous system tumors with heterogeneous clinical course. Considering that ependymomas in children are biologically distinct from their adult counterparts, this study aimed t... Read More about Integrative molecular characterization of pediatric spinal ependymoma: the UK Children’s Cancer and Leukaemia Group study.

A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups (2020)
Journal Article
Ritzmann, T. A., Rogers, H. A., Paine, S. M., Storer, L. C., Jacques, T. S., Chapman, R. J., …Grundy, R. G. (2020). A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups. Pediatric Blood and Cancer, 67(9), Article e28426. https://doi.org/10.1002/pbc.28426

Background: Relapse occurs in 50% of pediatric ependymoma cases and has poor prognosis. Few studies have investigated the clinical progress of relapsed disease, and treatment lacks a standardized approach. Methods and materials: We analyzed 302 pedia... Read More about A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups.

Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas (2018)
Journal Article
Pajtler, K. W., Wen, J., Sill, M., Lin, T., Orisme, W., Tang, B., …Ellison, D. W. (2018). Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathologica, 136(2), 211-226. https://doi.org/10.1007/s00401-018-1877-0

Of nine ependymoma molecular groups detected by DNA methylation profiling, the posterior fossa type A (PFA) is most prevalent. We used DNA methylation profiling to look for further molecular heterogeneity among 675 PFA ependymomas. Two major subgroup... Read More about Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.